Volume:
Day Range:
Last Trade Time:
Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Latest News
Likes Subject
Idiot sellers INFINITI 10/10/22 1:36 PM
Dip then rip again INFINITI 10/06/22 10:54 AM
Load up 500% doable here INFINITI 10/06/22 9:56 AM
Let’s run this bad boy cmon $$$$ INFINITI 10/06/22 9:46 AM
Whatever it is I’m in $$$$$ INFINITI 10/06/22 7:21 AM
https://reporter.am/2022/07/21/statera-biopharma-inc-nasdaqstab-short-interest-u oldgrowth28 07/22/22 11:25 AM
and yet a new scam in the making goforthebet 07/14/22 10:49 AM
Difficult to believe people were sucked into buying ssc 07/14/22 9:57 AM
why I am not surprised - lol goforthebet 05/24/22 1:32 AM
Wow, exciting stuff. How can stab still ssc 05/17/22 2:44 PM
The option agreement with the University of Pittsburgh bobbleheadtwin 05/17/22 11:29 AM
Well, you were right and I was wrong. maxmax47 05/11/22 1:26 PM
Huh? 200%? Try 500% plus. LOL. maxmax47 05/09/22 9:35 PM
So downside risk minimal and expecting a 200% ssc 05/05/22 11:45 PM
Sure... the dow got absolutely slaughtered and tanked maxmax47 05/05/22 10:46 PM
Nope, I bought back into the stock for maxmax47 05/05/22 10:37 PM
Got an update on stab movement today? ssc 05/05/22 12:18 PM
Agree mining101 05/05/22 10:21 AM
So you're a buyer here at .37? ssc 05/05/22 10:09 AM
They deleted my last reply. However, the stock maxmax47 05/05/22 10:07 AM
Do you have any idea about: ssc 05/02/22 4:44 PM
Perhaps. However, it is a 400 million dollar maxmax47 05/02/22 4:19 PM
There is a difference between being on a ssc 05/02/22 10:17 AM
I see you. Market makers trying to use dfloy 05/02/22 10:07 AM
Absolutely! But it did allow me to buy maxmax47 05/02/22 9:46 AM
Low volume price manipulation is rampant. dfloy 05/02/22 9:40 AM
I agree INFINITI 05/02/22 9:01 AM
Seriously? Projected revenue? From a term ssc 05/02/22 8:53 AM
yup! 400 mil in projected revenue... and it maxmax47 05/02/22 8:48 AM
Squeeeeeze mining101 04/29/22 2:13 PM
Lows almost tested - about to squeeze mining101 04/29/22 12:55 PM
Absolutely!!! .50 coming iwanttomakemoney 04/29/22 10:51 AM
Buy pullback chart still bullish sweet crude 04/29/22 10:48 AM
bounce coming!!! iwanttomakemoney 04/29/22 10:47 AM
.43 looks like a heavy load of this poc. ssc 04/29/22 9:35 AM
I guess the run to .50s will continue PennyPusher786 04/28/22 3:32 PM
Double Bottom at 43.50 and bounce off .40 Mac-A-Million 04/28/22 3:16 PM
huge news PinkPennies 04/28/22 12:36 PM
50’s almost there! Squeeeeeeze!!! $STAB bandit007 04/28/22 12:31 PM
STAB shorts G2G 04/28/22 12:20 PM
Here we goooo INFINITI 04/28/22 12:15 PM
Watch the .5 break INFINITI 04/28/22 12:01 PM
.5 INFINITI 04/28/22 11:58 AM
Looks like it may trend upwards to .50 PennyPusher786 04/28/22 11:46 AM
Creeping up to the high of day. If bandit007 04/28/22 11:40 AM
This is a beast INFINITI 04/28/22 11:39 AM
Moving up again now! $STAB bandit007 04/28/22 11:17 AM
Crazy volume, entire float has been turned over ssc 04/28/22 10:46 AM
What you think is a fair estimate today... PennyPusher786 04/28/22 10:15 AM
Their balance sheet looks like crap. Their most PennyPusher786 04/28/22 10:14 AM
Likes Subject

INFINITI
10/10/22 1:36 PM
INFINITI
10/06/22 10:54 AM
INFINITI
10/06/22 9:56 AM
INFINITI
10/06/22 9:46 AM
INFINITI
10/06/22 7:21 AM
goforthebet
07/14/22 10:49 AM
goforthebet
05/24/22 1:32 AM
maxmax47
05/11/22 1:26 PM
maxmax47
05/09/22 9:35 PM
maxmax47
05/05/22 10:37 PM
mining101
05/05/22 10:21 AM
ssc
05/05/22 10:09 AM
ssc
05/02/22 4:44 PM
dfloy
05/02/22 10:07 AM
maxmax47
05/02/22 9:46 AM
INFINITI
05/02/22 9:01 AM
mining101
04/29/22 2:13 PM
mining101
04/29/22 12:55 PM
iwanttomakemoney
04/29/22 10:51 AM
sweet crude
04/29/22 10:48 AM
iwanttomakemoney
04/29/22 10:47 AM
PennyPusher786
04/28/22 3:32 PM
Mac-A-Million
04/28/22 3:16 PM
PinkPennies
04/28/22 12:36 PM
bandit007
04/28/22 12:31 PM
G2G
04/28/22 12:20 PM
INFINITI
04/28/22 12:15 PM
INFINITI
04/28/22 12:01 PM
INFINITI
04/28/22 11:58 AM
.5
PennyPusher786
04/28/22 11:46 AM
bandit007
04/28/22 11:40 AM
INFINITI
04/28/22 11:39 AM
bandit007
04/28/22 11:17 AM
PennyPusher786
04/28/22 10:15 AM
PennyPusher786
04/28/22 10:14 AM

Statera BioPharma, Inc (STAB)

Followers
82
Posters
299
Posts (Today)
0
Posts (Total)
3366
Created
05/13/07
Type
Free
Moderators



PIPELINE https://www.staterabiopharma.com/pipeline/

Catalysts:
For years, the company has been developing its pipeline following three basic guidelines – a balanced approach, comprehensive and complex development as well as safety and foresight. By implementing those principles in its discovery, the company has created evolving therapeutics and continues to test and screen multiple cell types to ensure its drugs’ effectiveness.

In light of the company’s commitment, STAB recently reported major financial growth for 2021 with revenues of over $1.4 million – a 100% increase from the year-ago period. This massive increase was largely the result of the company’s acquisition of ImQuest Life Sciences, Inc. – a research and development company with a focus on cancer, inflammation and infectious disease treatments.

In terms of its expenses, STAB reported operating costs of over $31 million – a massive 191% increase from its year-ago period. Even though it is currently operating at a loss, CEO Michael Handley emphasized that STAB has “taken numerous steps to further develop its clinical stage pipeline.” As of now, it has invested in the expansion of clinical trial programs for its Crohn’s disease and COVID-19 drug treatments. For this reason, Handley believes the company is “well-positioned to achieve numerous milestones in 2022.”

The company seems poised for growth in the months ahead given that its all-stock deal to acquire ImQuest Life Sciences has previously provided STAB with the assets necessary to advance its internal drug development program. By integrating ImQuest BioSciences – the drug development department of ImQuest Life Sciences – into STAB’s existing drug development operations, the company can now offer a direct evaluation of all vaccines, biologics and pharmaceuticals in preclinical development.

In this way, STAB could capitalize on ImQuest BioSciences and its ability to achieve its mission of developing new immune therapies targeting cancers, infectious diseases and autoimmune disorders. This, in turn, will allow the company to develop a competitive advantage over other players in the industry.

As of now, STAB is developing a number of drug treatments covering several widespread diseases. Currently in its phase 2 trial, the company’s lead investigational drug candidate – STAT-201 – is developed for the treatment of pediatric patients with Crohn’s disease. After the FDA granted STAT-201 Orphan Drug Designation for the treatment of Crohn’s Disease in pediatric patients, STAB intends to initiate its Phase 3 clinical trials in the coming months. Given that Crohn’s disease affects an estimated 3 million US adults on an annual basis, the upside potential for this drug is looking promising.

The company is also capitalizing on the increase in demand for treatments of acute and post-acute COVID-19. Currently in phase 1 clinical trials, STAT-205 has the potential to treat these infections by modulating immune system functions and decreasing inflammatory responses affiliated with SARS-CoV-2 viral infections.

STAB is in prime position to achieve a breakthrough in its current studies given the proceeds from its latest direct offering. Handley has previously emphasized the company’s plans to “use proceeds from the direct offering to start the enrollment of patients in Q2 – in addition to including patients with acute COVID-19 infection in the company’s STAT-205 study”.

Recently, STAB announced it was granted approval by the Central Institutional Review Board to begin the Phase 3 clinical trial for STAT-201 in the treatment of pediatric Crohn’s Disease. Now that the sites are being selected, the company plans to include at least 165 patients in the trial – which is expected to begin as soon as Q2. As it initiates this trial, STAB could be among the best pharma stocks to buy this week.

Pancreatic cancer:

Statera is developing STAT-401 as an adjunct to standard of care therapy to extend the duration of disease remission in patients with pancreatic cancer. The U.S. Food and Drug Administration (FDA) granted STAT-401 Orphan Drug Designation for the disease. In August 2021, the company received feedback following a Type C meeting with the U.S. regulators regarding the STAT-401 clinical development program. The Company has established an advisory panel of oncology experts, and now expects to initiate a Phase 1b/2 clinical trial during the first half of 2022.


Michael K. Handley, President and CEO of Statera Biopharma, stated, “Pancreatic cancer remains a devastating disease despite the tremendous advances in cancer research. The American Cancer Society predicts that it could become the second-leading cause of cancer-related death behind lung cancer. We are harnessing our deep understanding of immune modulation to develop STAT-401 to help address this high need cancer population. With our advisory panel now in place, we look forward to advancing our clinical program and bringing hope to the patients and their families fighting this dreaded disease.

Statera Biopharma Submits Phase 1 Clinical Trial Protocol to FDA 

for Investigational Treatment of Long-Haul COVID-19

 

The Company expects to conclude enrollment during the third quarter and report topline results in the fourth quarter.



https://ir.staterabiopharma.com/news-releases/news-release-details/correction-statera-biopharma-submits-phase-1-clinical-trial
Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
STAB Latest News
Most Liked Posts
(Last 30 Days)
New Post